Clinical trials in lagundi as drug in COVID-19, approved by FDA – Dela Peña

Lagundi
Lagundi

The Food and Drug Administration (FDA) has approved clinical trials for lagundi as a supplemental treatment for those infected with COVID-19.

This was announced by the Department of Science and Technology (DOST) Sec. Fortunato dela Peña in Always Ready briefing.

Sec. Dela Peña, Philippine General Hospital (PGH) personnel will conduct the said clinical trials at the Quezon Institute quarantine center, Santa Ana Hospital and Philippine National Police-NCR community quarantine center.

“‘Yun pong sa lagundi, ang good news po ay naaprubahan na ng FDA ang clinical trials. Ito lang early this week naaprubahan,”said Sec. Dela Peña.

According to Sec. Dela Peña, will conduct clinical trials in mild cases.

“Ang hangad natin diyan ay ma-address ‘yung symptoms na katulad ng ubo, lagnat at mga sore throat. Kasi malaking bagay kung giginhawa ang ating pasyente na may cases diyan sa symptoms na ‘yan,”added Sec. Dela Peña.

Meanwhile, there has been no FDA approval in the clinical trials of laughter.

Leave a Reply

Your email address will not be published.